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The neurohormone oxytocin (OT), consisting of nine amino acids, is produced 
in the hypothalamus and secreted from the posterior lobe of the pituitary gland. 
Recent studies show that OT can affect the course of the disease and is promising in 
the treatment of neurodegenerative disorders, due to its therapeutic properties and 
benefits. Histological and biochemical findings of the studies on vincristine-induced 
neuropathy, cisplatin-induced cytotoxicity, diabetic neuropathy, rotenone-induced 
Parkinson’s disease, hypoxia, and stroke, which are reviewed in this chapter, revealed 
that OT significantly prevented neuronal damage with its anti-inflammatory and 
antioxidant properties. Therefore, the neuroprotective effects of OT and the under-
lying molecular mechanisms continue to attract the attention of scientists.
Keywords: oxytocin, neurohormone, neuroprotection
1. Introduction
The neurohypophyseal nonapeptide hormone oxytocin (OT), the first peptide 
hormone to have its structure determined [1], plays an important role in social 
behavior across a wide variety of species [2, 3]. The word ‘oxytocin’ was coined 
from the Greek words (ω k ν ξ, τ o k ox ξ) meaning ‘quick birth’ after its uterine-
contracting properties were discovered by Dale [4]. OT’s repertoire has expanded 
to maintain a central role in more complicated aspects of reproductive behavior. For 
these reasons, it is called the great facilitator of life [5] (Figure 1).
OT is synthesized at the paraventricular (PVN), supraoptic nuclei (SON), and 
intermediate accessory nuclei of the hypothalamus and transported through the 
axons of these cells to the posterior pituitary gland [6]. From the posterior pituitary, 
OT reaches the general blood circulation. It is also produced by different peripheral 
tissues, such as skin, placenta, ovary, testis, thymus, pancreas, adipocytes, kidney, 
heart, and blood vessels [7]. OT acts as a hormone in the peripheral circulation and 
as a neurotransmitter/neuromodulator in the central nervous system [8].
The neurohormone OT is an effective stimulant of the uterine contraction and 
is used primarily to induce or reinforce labor in obstetrics [9]. OT facilitates the 
expulsion of milk from the mammary gland during nursing. The release of OT 
from the posterior pituitary is stimulated by tactile sensory inputs from the nipple. 
Milk-ejection is the only physiological function known to absolutely require OT 
[10]. For both men and women, OT is released during sexual stimulation and 
orgasm, may reduce urine volume and induce natriuresis through co-activation 
of vasopressin receptors, and is involved in the modulation and regulation of the 
hypothalamic–pituitary–adrenal (HPA) axis [11]. Moreover, OT plays a role in the 
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endocrine and paracrine activities such as various sexual and maternal behaviors, 
social recognition, aggression, neuromodulation, cognition, and tolerance develop-
ment; however, the mechanism is still unclear [2, 12, 13].
The central neuropeptidergic effect of OT has continued to be studied in 
the social behavior of various species (in humans and animal models) to date. 
Nagasawa et al. summarized the behavioral and physiological oxytocin-induced 
effects with the title of “summary of the role of the oxytocin system in reciprocal 
communication” in Figure 2 [14].
According to the figure, the central OT secretion is stimulated by multiple 
sensory signals in mammals. Increased OT release is important in the develop-
ment of physiology and behavioral functions, and also causes a decrease in pain 
and stress.
Figure 1. 
A simple cycle of life illustrates numerous points at which OT may affect behaviors and physiology to facilitate 
the propagation of the species [5].
Figure 2. 
“Summary of the role of the oxytocin system in reciprocal communication” Nagasawa et al. [14].
3
Oxytocin and Neuroprotective Effects
DOI: http://dx.doi.org/10.5772/intechopen.96527
2. Chemical properties of oxytocin
Oxytocin (seq;CYIQNCPLG), a neurohypophysial peptide hormone, consists of 
nine amino acids (H-Cys(1)-Tyr-Ile-Gln-Asn-Cys(1)-Pro-Leu-Gly-NH2) linked with 
a [1-6] disulfide bond and a semi-flexible carboxy amidation tail [15] (Figure 3). This 
results in a peptide constituted of a rigid N-terminal cyclic 6-residue ring structure 
and a flexible COOH-terminal alpha amidated three-residue tail [5].





Chemical structure depiction of oxytocin (OT). Molecular formula: C43H66N12O12S2/Molecular weight: 
1007.2 g/mol [15].
Figure 4. 
“Schematic diagram of the oxytocin (OT) and vasopressin (AVP) genes (large arrows), preprohormones 
(boxes), and neuropeptides (bottom)” [16].
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The structure of OT is very similar to another nonapeptide, entitled vasopressin 
(AVP/arginine vasopressin), which differs from OT by only two amino acids in posi-
tions 3 and 8 (Figure 4) [16], (Figure 5) [9]. OT and AVP genes in the mouse, rat, and 
human genomes are located on the same chromosome separated by a short (3.5–12 
kbp) intergenic region but are in opposite transcriptional orientations [17–20]. They 
are synthesized in the brain’s hypothalamic paraventricular and supraoptic nuclei [21].
3. Oxytocin receptor, cellular actions, and signaling
OT is currently known to have only one receptor (OTR/oxytocin receptor), 
which forms together with the related V1a, V1b, and V2 vasopressin receptor 
subtypes a subfamily of the large G protein-coupled receptor (GPCR) superfamily, 
one of the most abundant protein classes in the mammalian genome [16, 22]. OT 
shows its biological activity through the GPCR, which is widely expressed through-
out the body, including the central and peripheral nervous systems. Heterotrimeric 
G-proteins are composed of α, β, and γ subunits [23]. These receptors are charac-
terized by seven putative transmembrane domains, three extracellular, and three 
intracellular loops (Figure 6) [9, 22, 24].
The group of OT and vasopressin receptors is well suited for receptor structure–
function analysis, because it comprises four related receptors that bind, with varying 
degrees of specificity, the two closely related peptide ligands, OT and vasopressin [25].
OTR can be coupled to different G proteins, leading to different intracellular 
pathways. It is possible that these various signaling pathways are differentially 
expressed in neuronal versus peripheral tissues [26].
The quality of specific acute or long-term neuronal effects of OT is dependent 
on the regional and subcellular presence of OTR, the characteristics of OT-OTR 
binding, and subsequent activation of intraneuronal signaling cascades. In addi-
tion, the formation of OTR homodimers or heterodimers with other receptors 
is likely to influence OTR affinity and downstream signaling [23]. The classical 
signaling pathway associated with the OTR involves a phospholipase C-mediated 
increase in phosphoinositide hydrolysis, activation of protein kinase C, and a rise in 
intracellular calcium [27, 28]. The proliferative effects of OT are mediated primarily 
by the activation of the MAP kinase pathway, involving different G protein-linked 
pathways as well as receptor tyrosine kinase transactivation [29].
Figure 5. 
“Organization of the oxytocin (OT) and vasopressin (VP) gene structure including a schematic depiction of the 
putative cell-specific enhancers (open circle, enhancer of OT gene; shaded circle, enhancer of VP gene)” [9].
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OT-induced Ca2 influx also seems to play a role in neuronal OT responses. On a 
cellular level, the OTR activates numerous Ca2-related and MAPK-related signaling 
cascades in a variety of cell types [23].
Given the multiple signaling pathways in which OTR binds, the development of 
pathway-specific ligands will be important in elucidating the different OTR-linked 
pathways, as well as developing more specific agonists and antagonists for future 
therapeutic applications.
4. Neuroprotective effects of oxytocin hormone
In mammals, increasing brain OT levels promotes attachment and attachment 
behavior, facilitates parental behavior, social recognition, and memory between rel-
atives, and establishes emotional bonds between animals and caregivers [11, 30–32]. 
In humans, it has been also shown to increase trust and generosity, strengthen emo-
tional and cognitive empathy, and reduce social-anxiety and fear-related behavior 
[33, 34]. In line with these findings, impaired social behavior profiles have been 
associated with reduced central endogenous OTergic activity. Depletion of OTergic 
signaling through genetic change of the OT gene or receptor has caused convincing 
social deficiencies, social amnesia, malfunctions in breastfeeding and maternal 
nutrition, and decreased infant ultrasonic sounds in response to social isolation, but 
normal birth and sexual behavior [35–37].
Abnormal brain development, during embryogenesis, fetal development, or 
early postnatal periods, can generate cognitive dysfunction as well as neurologi-
cal, emotional, and behavioral disorders. Disturbed brain OTergic signaling has 
been implicated in several psychiatric disorders where social dysfunction is a core 
symptom (autism spectrum disorder, social anxiety, borderline personality disorder, 
addiction, and schizophrenia) [31, 37, 38].
There are several animal studies in the literature showing neuroprotective 
effects of OT. These neuroprotective effects of OT hormone include social neuro-
protection, oxygen–glucose deprivation resistance, immune system modulation, 
anti-apoptotic, anti-inflammatory, and antioxidative functions [38, 39].
Figure 6. 
“Schematic model of the structure of the OT receptor and its interaction with the ligand” (Zingg HH and 
Laporte SA, 2003) [22].
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Due to the therapeutic properties and health benefits of OT, it can be thought 
that OT and OT-like molecules are a part of ‘natural medicine’ that can both prevent 
and treat diseases and affect the course of many diseases [20].
Understanding the complex actions of OT requires awareness that OT regulates 
not only the brain and reproductive system but also the immune and autonomic 
nervous systems. For example, evidence supporting the coordinated effects of 
acetylcholine (the neurotransmitter in the preganglionic sympathetic and parasym-
pathetic neurons) and OT regulate the autonomic nervous system [40].
The therapeutic effects of the OT hormone have been studied in a variety of 
pathological conditions, both in vitro and in vivo.
OT treatment in rats induces several long-lasting anti-stress effects, for exam-
ple, subchronic OT treatment of males and females rats produces a long-lasting 
change in spontaneous motor activity, nociception threshold, and weight gain [41].
In many studies, the antiepileptic properties of OT have been emphasized which 
have positive effects on neurobehavioral pathologies such as autism and psychosis, 
and it has been shown that it has healing effects on these diseases with its anti-
inflammatory and antioxidant properties [42].
It has been revealed that OT modulates the immune and anti-inflammatory 
response thus reducing inflammatory cytokines production (TNFα; tumor necrosis 
factor-alpha; is a multifunctional cytokine and IL-6 (interleukin 6)); added to its 
remarkable anabolic properties on many peripheral organs and on the immune 
system development [38, 43, 44].
Studies demonstrate the therapeutic effects of both melatonin and OT on  
critical disease polyneuropathy (CIP) are remarkable. These effects appear to be 
associated with suppression of cytokine production and improvement in antioxidant 
capacity [45].
4.1 Vincristine-induced neuropathy
In a study, scientists evaluated the therapeutic potential of OT and liraglutide 
(LIR), which is a long-acting human glucagon-like peptide-1 (GLP-1) analog, in 
a rat model of vincristine-induced neuropathy [46]. Vincristine (VCR) is a vinca 
alkaloid, is known to cause various neurological dysfunctions, antitumoral, and the 
most neurotoxic agent and it has been used for the treatment of numerous tumors 
[47, 48]. GLP-1 is a polypeptide hormone composed of 30 amino acids, which is 
mainly secreted from intestinal L cells in response to nutrient ingestion [49]. Recent 
studies have indicated that GLP-1 analogs may have therapeutic effects against 
central and peripheral degenerative changes in animal models of neurodegenera-
tive diseases [50]. GLP-1 exerts its neurotrophic effects through GLP-1 receptors 
(GLP-1Rs), which are detected particularly on neurons throughout the central and 
peripheral nervous system [51]. Histological and biochemical findings of the study 
revealed that both OT and liraglutide significantly prevented neuronal damage by 
suppressing lipid peroxidation and inducing NGF (nerve growth factor) expression 
in VCR-received rats [46].
4.2 Cisplatin-induced cytotoxicity
Platinum drugs are compounds containing metal ions that form binding sites 
for proteins, nucleic acids, and other cellular molecules. This property is largely 
responsible for the biological activity of drugs as well as their toxicity [52]. 
Peripheral neurotoxicity is the dose-limiting factor for clinical use of platinum 
derivatives, a class of anticancer drugs that includes cisplatin, induce decreased 
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neural transmission rate, loss of vibration and position senses, tingling paresthesia, 
dysesthesia, loss of tendon reflexes, tremor, ataxia, and muscle weakness [53, 54].
Cisplatin (CP) was the first heavy metal compound to be used as antineoplastic, 
and since its approval by the FDA in 1978, it is one of the most widely used for the 
treatment of various solid tumors such as lung, ovary, testis, bladder, head, and 
neck, and cervical and endometrial cancers [55, 56].
The mechanisms suggested explaining the neurotoxicity of these drugs are 
dorsal root ganglia alteration, oxidative stress involvement, and mitochondrial dys-
function. These alterations are able to stop DNA replication and cell cycle, inhibit 
DNA repair mechanisms, and induce cell death through apoptosis [57]. Oxidative 
stress, DNA damage, and inflammatory cytokines play a major role in the mecha-
nism of cisplatin-induced cytotoxicity. Cisplatin increases the production of free 
oxygen radicals and decreases the antioxidants, thus resulting in the deterioration 
of the oxidant/antioxidant balance and accumulation of reactive oxygen radicals 
(ROS) in tissues [58]. Akman et al. clearly demonstrated the protective effect of 
OT in cisplatin-induced neurotoxicity [12]. The neuroprotective effect seems to be 
associated with antioxidant (by the suppression of lipid peroxidation and increas-
ing the antioxidative capacity) and anti-inflammatory (by decreasing the plasma 
TNF-α levels) activity of OT [12]. The imbalance between oxidative and antioxi-
dative mechanisms may play an important role in triggering axonal injury [59]. 
Axonal transport is important for axonal integrity. Excessive ROS production causes 
distal axonal degeneration and interruption of axonal transportation. It is demon-
strated that OT decreases the free oxygen radicals in the brain membranes, prevents 
low-density lipoprotein oxidation, and inhibits lipid peroxidation [60, 61]. OT 
decreases the levels of proinflammatory mediators such as TNF-α, IL-4 (interleukin 
4) and 6, macrophage inflammatory proteins 1a and 1b, monocyte chemoattractant 
protein-1, and vascular endothelial growth factor in lipopolysaccharide-induced 
inflammatory response and endotoxemia [62].
4.3 Diabetic neuropathy
Present results also demonstrate that OT appears to alleviate the harmful 
effects of hyperglycemia on peripheral neurons by suppressing inflammation, 
oxidative stress, and apoptotic pathways [63]. Excessive ROS accumulation leads 
to an increase in mitochondrial inner membrane permeability. Hyperglycemia also 
increases oxidative stress and inhibits mitochondrial biogenesis [64]. The depletion 
of growth factors and the activation of caspase 3 and caspase 8 trigger intrinsic 
apoptotic cell death in neurons [65, 66].
Diabetic polyneuropathy (DNP) is the most common complication of diabetes 
with a prevalence of 60–70%. DNP represents a heterogeneous group of syndromes 
with clinical and subclinical disorders and abnormalities such as distal symmetrical 
polyneuropathy, mononeuropathy, diabetic amyotrophy, autonomic dysfunction, or 
cranial neuropathies [67]. Hyperglycemia-induced metabolic changes affect tissues 
and microvascular systems and lead to ischemic pathological changes in the nerve 
tissue [68]. Erbas et al. assessed the neuroprotective and neurorestorative effects of 
exogenously administered OT on diabetic neuropathy in rats by electrophysiologi-
cal, biochemical, histological, and immunohistochemical parameters [63]. They 
demonstrated the potent anti-oxidant and anti-inflammatory effects of different 
doses of OT on sepsis-induced neuropathy in rats. According to their EMG (electro-
myography) findings, OT treatment either rescued and/or restored neuromuscular 
performance in a dose-dependent manner. Following OT treatments, a significant 
decrease in MDA (malondialdehyde) levels, and a significant increase in GSH 
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(glutathione) levels were detected. The results showed us OT alleviates the harmful 
effects of hyperglycemia on peripheral neuronal cells by suppressing inflammation, 
oxidative and apoptotic pathways [63].
4.4 Rotenone induced Parkinson’s disease
The brain is the most complex human organ and is extremely sensitive to 
the action of external chemicals and/or physical factors during its ontogenesis. 
Exposure to xenobiotics has raised great concern about the increasing prevalence 
of neurodevelopmental disorders and the possible unknown developmental neuro-
toxic effects of certain chemicals and drugs [69, 70].
Rotenone is a commonly used plant-derived pesticide that inhibits mitochondrial 
complex I of the electron transport chain [71]. Rotenone has been suggested as one of 
the most important environmental risk factors for Parkinson’s Disease (PD) [72, 73]. 
Clinical and experimental studies have strongly supported that it is not only the SNc 
(substantia nigra pars compacta) and striatum, but also other regions, such as ventral 
tegmental area (VTA), have important roles in the pathophysiology of PD [74–76]. 
Accumulating evidence indicates that OT exerts its cytoprotective effects via anti-
oxidative, anti-apoptotic, and anti-inflammatory pathways [44, 77, 78]. In recent 
years, rotenone-induced PD model in rats is commonly used to study the mechanisms 
of neuronal degeneration in PD. Erbas et al. observed a considerable cytoprotective 
effect of OT on cell death in dopaminergic neurons due to rotenone toxicity [79]. In 
the study, immunohistochemical evaluation of the brains showed decreased tyrosine 
hydroxylase immunoreactivity in saline-treated PD animals whereas OT administra-
tion significantly enhanced TH (tyrosine hydroxylase) expression in the striatal 
neurons. Considering that caspase activities play an important role in rotenone-
induced cell death, the results obtained from the study revealed that OT reduces 
apoptosis by affecting mitochondrial caspase pathways and death signals [79]. In vivo 
and in vitro studies demonstrate that OT has a triggering role in cell proliferation and 
neurogenesis [80, 81].
4.5 Hypoxia
The factors that cause brain damage are varied. These factors include inflam-
mation, birth trauma, tumors, stroke, ischemia, and hypoxia, as well as metabolic 
and genetic disorders. Hypoxia is the insufficient oxygen supply of the cell. It leads 
to neurodegeneration by causing mitochondrial dysfunction. Disruption of aerobic 
respiration mechanism causes different degrees of hypoxia in the tissue. As a result 
of damage, neurodegeneration, and brain dysfunction accompanied by cognitive 
impairment are observed [82–84]. Depending on the degree of hypoxia, activa-
tion of potassium channels, increase in perivascular PH, elevated blood and tissue 
concentrations of CO2, variation in intracellular calcium levels may contribute to 
neurodegeneration [85]. Regardless of neuronal damage, another factor underly-
ing hypoxia-induced neonatal seizures may be a decrease in gamma-aminobutyric 
acid (GABA) activity [42, 86]. The cerebral cortex, hippocampus, striatum, and 
cerebellum have been shown to be the primary areas that are significantly affected 
by hypoxia and these regions have been associated with the resultant long-term 
cognitive problems in animal models [87]. In 2018, Panaitescu et al. reported 
that OT showed hippocampal neuroprotective effects and reduced the number 
of cumulative seizures in hypoxia-induced rats [88]. OT suppresses inflamma-
tion in the central nervous system and has another vital role that concerns GABA 
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(gamma-aminobutyric acid; a neurotransmitter in the brain); it alternates the 
GABAergic neurons from depolarizing to hyperpolarizing in terms of support-
ing normal anoxia associated with labor and delivery [88–90]. In a study, results 
showed that OT treatment given in the acute period of hypoxia had ameliorative 
effects on PTZ (pentylenetetrazol; a GABA(A) receptor antagonist)-induced 
convulsions in the long term. Also, it was observed significantly decreased TNF-α 
level in both of the hypoxia groups that were given OT treatment [91]. Possible 
mechanisms of this effect were hormone suppresses inflammation and reduces 
hippocampal gliosis, and anticonvulsant effect by increasing GABAergic activity. 
That conclusion was exemplified by the significantly decreased TNF-α level in both 
of the hypoxia groups that were given OT treatment. Brain inflammation caused by 
LPS (lipopolysaccharide) is characterized by neuronal loss and microglial activa-
tion. Findings have demonstrated that OT suppressed lipopolysaccharide-induced 
microglial activation [91, 92]. Studies also have shown that OT reduces the release 
of cytokines such as TNF-α, IL-6, IL-1β (interleukin 1 beta), IFN-γ (interferon-
gamma) by suppressing inflammation [93].
4.6 Stroke
Stroke is a sudden decrease or cessation of blood flow to the brain. It can occur 
when one of the brain vessels ruptures and blood bleeds into the brain tissue or 
brain membranes. This is known as “brain hemorrhage”. Depending on the affected 
brain region, speech, muscle strength, coordination-balance, vision, or memory 
loss occur. Technical advances in neuroimaging and neuropathology have facilitated 
the understanding of ischemia, infarction, and hemorrhage in the brain [94]. 
Neuronal injury in stroke is caused by different mechanisms, including excitotoxic-
ity, inflammation, oxidative stress, and apoptosis [95].
Cerebral ischemia induces microglial activation by a strong inflammatory reac-
tion with peripheral leukocyte influx into the cerebral parenchyma. Interruption of 
cerebral blood flow causes necrotic neuron death by affecting energy metabolism. 
In addition, different immune responses occur and inflammatory cell activation 
develops. Inflammatory cells can release a variety of cytotoxic agents including 
more cytokines, matrix metalloproteinases (MMPs), nitric oxide (NO), and more 
ROS (Figure 7) [95, 96].
One of the dramatic events during ischemia is the increase in intracellular 
calcium (Ca + 2), which leads to the activation of calpain proteases [97]. A study 
shows that calpain-1 increases reactive oxygen species levels and inflammatory 
cytokines [98]. Increased oxidative stress followed by calcium influx, mitochon-
drial dysfunction, and the loss of cytoskeletal proteins are phenotypes commonly 
observed in Alzheimer, Huntington, and Parkinson’s diseases, as well as amyo-
trophic lateral sclerosis, stroke, ischemia, spinal cord injury, and TBI (traumatic 
brain injury) [99].
Neuroprotective effects of OT and the underlying molecular mechanisms are 
under discussion after different ischemia–reperfusion models [100, 101]. Jankowski 
et al reported that treatment with OT after cardiac ischemic induction in rats can 
reduce myocardial infarct size and improve heart function [102]. In a study, Etehadi 
et al showed a significant decrease in calpain-1 expression after OT administration 
in the tMCAO (transient middle cerebral artery occlusion) model. This refers to 
the neuroprotective role of OT, which could result in the inhibition of calpain [38]. 
Overall, these findings will add to our knowledge of the positive effects of OT on 
the outcomes of stroke.
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5. Summary and dıscussıon
The effect of oxytocin as a neuromodulator is a subject that has been studied in 
many different ways. It effectively provides nerve regeneration in nerve damage is 
a known issue. In addition, its anti-epileptic attack or reducing attack power effect 
in epilepsy models has also been shown in some studies. It plays an important 
role in the regulation of spinal autonomic functions. Although it regulates urina-
tion reflex and uterine motility, it can increase heart rate and renal sympathetic 
activity. Considering the positive effects of OT on the brain, reproductive system, 
immune and autonomic nervous system it shows promise as future treatment 
agents on the spectrum of anxiety, autism, personality disorders, and neurode-
generative disorders. Studies reveal that oxytocin shows its cytoprotective effects 
through its anti-inflammatory, anti-apoptotic and antioxidant properties. In 
chronic inflammation, immune cells constantly attack healthy tissues, resulting in 
Figure 7. 
“Brain ischemia triggers inflammatory responses due to the presence of necrotic cells, generation of reactive 
oxygen species (ROS), and production of inflammatory cytokines even within neurons” (Wang Q et al. 
2007) [95].
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conditions such as obesity, cancer, diabetes, heart disease, autoimmune diseases, 
Alzheimer’s, and some other diseases. Increasing the effectiveness of anti-inflam-
matory agents such as OT will improve the quality of life by changing the course of 
many diseases.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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